Expression of activation markers CD23 and CD69 in B-cell non-Hodgkin's lymphoma

European Journal of Haematology

Volumn 60, Issue 2, 1998, Pages 125-132

  Erlanson, M ^a   Gronland E ^a   Lotvenberg E ^a   Roos, G ^a   Lindh, J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

CD23; CD69; Flow cytometry; Non Hodgkin's lymphoma; Prognosis

Indexed keywords

CD23 ANTIGEN; CD69 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISONE; STEROID; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 0031953552     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01009.x     Document Type: Article

References (26)

1. KNAPP W, RIEBER P, DÖRKEN B, SCHMIDT RE, STEIN H. VAN DEM BORNE AEG. Towards a better definition of human leucocyte surface molecules. Immunol Today 1989: 10: 253-258.
2. GORDON J, CAIRNS J, LIU Y-J, et al. A novel multifunctional regulator of the immune system that binds IgE. GORDON J, ed. Monogr Allergy. Basel: Karger, 1991: 29: 156-168.
3. PALLESEN G. The distribution of CD23 in normal human tissue and in malignant lymphomas. In: MCMICHAEL AJ, ed. Leucocyte typing III. International Workshop and conference on human leucocyte differentiation antigens. Oxford: Oxford University Press, 1987: 383-386.
4. GORDON J, ROWE M, WALKER L, GUY G. Ligation of the CD23, p45 (BLAST-2, EBVCS) antigen triggers the cell-cycle progression of activated B lymphocytes. Eur J Immunol 1986: 16: 1075-1080.
5. GUSTAVSSON S. The role of CD21 and CD23 in immune responses. Thesis, Uppsala University, 1996.
6. HARRIS NL, JAFFE ES, STEIN H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994: 84: 1361-1392.
7. REINISCH W, WILLHEIM M, HILGARTH M, et al. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 1994: 12: 2146-2152.
8. TESTI R, PHILIPS J, LANIER L. T cell activation via Leu-23 (CD69). J Immunol 1989: 143: 1123-1128.
9. TESTI R, PHILIPS J, LANIER L. Leu 23 induction as an early marker of functional CD3/T cell antigen receptor triggering. J Immunol 1989: 142: 1854-1860.
10. - B lymphocytes. Int Immunol 1990: 2: 603-614.
11. - lymphocytes. Cell Immunol 1992: 141: 342-351.
12. DEBLANDRE G, LEO O, HUEZ G, WAHTHELET M. CD69 is expressed on Daudi cells in response to interferon alfa. Cytokine 1992: 4: 36-43.
13. STANSFELD A, DIEBOLD J, KAPANCI Y, et al. Updated Kiel classification for lymphomas. Lancet 1988: 1: 292-293.
14. HIDDEMAN W, LONGO DL, COIFFER B, et al. Lymphoma classification - the gap between biology and clinical management is closing. Blood 1996: 88: 4085-4089.
15. VINDELØV LL, CHRISTENSEN IJ, NISSEN NI. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983: 3: 323-327.
16. ZUKERBERG L, MEDEIROS L, FERRY J, HARRIS N. Diffuse low-grade B-cell lymphomas: four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. Am J Clin Pathol 1993: 100: 373-385.
17. KIPPS T. The CD5 B cell. Adv Immunol 1989: 47: 117-185.
18. INGHIRAMI G, FOITL D, SABICHI A, KNOWLES D. Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterisation, including IgVH gene and CD5 antigen expression. Blood 1991: 71: 1503-1515.
19. YUKAWA K, KIKUTANI H, OWAKI H, et al. A B-cell specific differentiation antigen, CD23, is a receptor for IgE (FceR) on lymphocytes. J Immunol 1987: 138: 2576-2580.
20. STEIN H, GERDES J, MASON D. The normal and malignant germinal centre. Clin Haematol 1982: 11: 531-559.
21. SALTER D, KRAJEWSKI A, CUNNINGHAM S. Activation and differentiation antigen expression in B-cell non-Hodgkin's lymphoma. J Pathol 1988: 154: 209-222.
22. KIMBY E, MELLSTEDT H, BJÖRKHOLM M, HOLM G. Clonal cell surface structures related to differentiation, activation and homing in B-cell chronic lymphocytic leukemia and monoclonal lymphocytosis of undetermined significance. Eur J Haematol 1989: 43: 452-459.
23. CARLSSON M, HASSAN IB, PAUL G, SUNDSTRÖM C, NILSSON K, TÖTTERMAN TH. Hairy cell leukemia (HCL) associated antigen B-ly7 is an activation/differentiation-associated antigen on HCL and normal B cells but not B-type chronic lymphocytic leukemia (B-CLL) cells. Leuk Lymph 1992: 6: 133-143.
24. SONNEVELD P, De RIDDER M, VAN DER LELIE H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995: 13: 2530-2539.
25. BEZWODA W, RASTOGI RB, ERAZO-VALLA A, et al. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group. Eur J Cancer 1995: 31A: 903-911.
26. PAVLOVSKY S, SANTARELLI MT, ERAZO A, et al. Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. Ann Oncol 1992: 3: 205-209.